Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006. Kolon Life Science Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Metrics to compare | 102940 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship102940PeersSector | |
---|---|---|---|---|
P/E Ratio | −5.3x | −2.9x | −0.5x | |
PEG Ratio | 0.04 | 0.01 | 0.00 | |
Price/Book | 1.4x | 0.9x | 2.6x | |
Price / LTM Sales | 2.5x | 0.8x | 3.2x | |
Upside (Analyst Target) | - | 39.1% | 41.4% | |
Fair Value Upside | Unlock | 14.9% | 6.0% | Unlock |